Hudson Bay Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Hudson Bay Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,020,985	Closed	-$188M	–	1188
2021 Q2	$188M	Buy	1,020,985 +20,463	+2%	+$3.51M	2.27%	5
2021 Q1	$153M	Buy	1,000,522 +636,422	+175%	+$98.4M	1.89%	8
2020 Q4	$56.9M	Buy	364,100 +128,500	+55%	+$16.5M	0.61%	21
2020 Q3	$27M	Sell	235,600 -6,400	-3%	-$690K	0.4%	34
2020 Q2	$27.2M	Buy	242,000 +42,000	+21%	+$4.46M	0.48%	30
2020 Q1	$18M	Buy	200,000 +6,300	+3%	+$618K	0.45%	34
2019 Q4	$20.9M	Buy	193,700 +28,700	+17%	+$3.07M	0.47%	35
2019 Q3	$16.2M	Buy	165,000 +110,000	+200%	+$12.4M	0.45%	40
2019 Q2	$7.2M	Buy	55,000 +30,000	+120%	+$3.87M	0.17%	132
2019 Q1	$3.38M	Sell	25,000 -61,400	-71%	-$7.63M	0.04%	361
2018 Q4	$8.41M	Buy	86,400 +26,200	+44%	+$3.1M	0.11%	168
2018 Q3	$8.37M	Buy	60,200 +30,200	+101%	+$3.79M	0.1%	178
2018 Q2	$3.73M	Sell	30,000 -30,000	-50%	-$3.51M	0.05%	362
2018 Q1	$6.69M	Sell	60,000 -10,000	-14%	-$1.2M	0.14%	172
2017 Q4	$8.37M	Buy	70,000 +30,000	+75%	+$3.65M	0.18%	92
2017 Q3	$5.61M	Sell	40,000 -30,000	-43%	-$4.08M	0.14%	133
2017 Q2	$8.52M	Sell	70,000 -75,000	-52%	-$8.73M	0.17%	125
2017 Q1	$17.6M	Buy	145,000 +40,000	+38%	+$5.16M	0.24%	87
2016 Q4	$12.8M	Buy	+105,000	New	+$12.8M	0.27%	77
2014 Q3	–	Sell	-40,000	Closed	-$6.25M	–	259
2014 Q2	$6.25M	Sell	40,000 -35,000	-47%	-$5.53M	0.19%	92
2014 Q1	$11.4M	Sell	75,000 -3,700	-5%	-$588K	0.31%	66
2013 Q4	$10.5M	Sell	78,700 -99,139	-56%	-$11.9M	0.43%	53
2013 Q3	$20.7M	Buy	+177,839	New	+$19.5M	0.76%	39

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Hudson Bay Capital Management's ALXN Position: Q3 2021 in Review

Hudson Bay Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,020,985 shares — an estimated $188M sold.

Hudson Bay Capital Management first reported a position in ALXN in Q3 2013 and held it in 23 quarters. The position peaked at $188M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Hudson Bay Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Hudson Bay Capital Management sold 1,020,985 Alexion Pharmaceuticals shares in Q3 2021, an estimated $188M.
Hudson Bay Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 23 quarters.
Hudson Bay Capital Management's Alexion Pharmaceuticals position peaked at $188M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Hudson Bay Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.